news

2024-11-13

PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.

Year:

2023-04-10

Congratulations! Risen laned in “KPMG China Biotech Future Sector 50 Ranking”

2023-03-13

Congratulations! Risen was entitled as a "special and innovative" small to medium-sized enterprise in Shanghai

2023-02-03

First in China: ANGPTL3 siRNA drug developed Risen and TopAlliance jointly approved for clinical trial.

2022-11-22

Congratulations! Risen successfully acquired the identification as the national high-tech enterprise!

2021-10-19

Risen signed a strategic cooperation agreement with China Merchants Bank Shanghai Branch

Shanghai Zhangjiang R&D Center.

Suzhou Industrial Park R&D Center.